Pregnancy Outcome After Methotrexate Treatment for Rheumatic Disease Prior to or During Early Pregnancy: A Prospective Multicenter Cohort Study
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Objective: High‐dose methotrexate (MTX) exposure during pregnancy is associated with embryopathy. The teratogenic potential of MTX at dosages typically used in the treatment of rheumatic diseases remains uncertain. The aim of this study was to evaluate the risk of spontaneous abortion, major birth defects, elective termination of pregnancy, shortened gestational age at delivery, and reduced birth weight in women exposed to MTX. Methods: Pregnancy outcome in women taking MTX (≤30 mg/week) either after conception or within the 12 weeks before conception was evaluated in a prospective observational multicenter cohort study. Pregnancy outcomes in the MTX group were compared to outcomes in a group of disease‐matched women and a group of women without autoimmune diseases (neither group was exposed to MTX). Results: The study sample included 324 MTX‐exposed pregnancies (188 exposed post‐conception, 136 exposed pre‐conception), 459 disease‐matched comparison women, and 1,107 comparison women without autoimmune diseases. In the post‐conception cohort, the cumulative incidence of spontaneous abortion was 42.5% (95% confidence interval [95% CI] 29.2–58.7), which was significantly higher than the incidence of spontaneous abortion in either comparison group. The risk of major birth defects (7 of 106 [6.6%]) was elevated compared to both the cohort of women without autoimmune diseases (29 of 1,001 [2.9%]) (adjusted odds ratio [OR] 3.1 [95% CI 1.03–9.5]) and the disease‐matched cohort (14 of 393 [3.6%]) (adjusted OR 1.8 [95% CI 0.6–5.7]). None of the malformations were clearly consistent with MTX embryopathy. Neither the cumulative incidence of spontaneous abortion (14.4% [95% CI 8.0–25.3]) nor the risk of major birth defects (4 of 114 [3.5%]) was increased in the pre‐conception cohort. Elective termination rates were increased in both of the MTX‐exposed cohorts. There were no other significant differences among groups in other study end points. Conclusion: Post‐conception administration of MTX at dosages typically used in the treatment of rheumatic diseases was associated with an increased risk of major birth defects and spontaneous abortion. Such evidence was not found among women in our pre‐conception cohort.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
McCaffrey, D. F., Ridgeway, G., & Morral, A. R. (2004) · Psychological Methods · doi:10.1037/1082-989x.9.4.403 · Cited by 1,317 · cited 1×
“Propensity score estimation used boosted regression trees (40), including maternal age, alcohol consumption, smoking status, and parity as covariates, and was repeated for each analysis.”
Method
Cited by
Götestam Skorpen, C., Hoeltzenbein, M., Tincani, A., Fischer-Betz, R., Elefant, E., Chambers, C., da Silva, J., Nelson-Piercy, C., Cetin, I., Costedoat-Chalumeau, N., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208840 · Cited by 1,068
Self-citationThe Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy
Nguyen, G. C., Seow, C. H., Maxwell, C., Huang, V., Leung, Y., Jones, J., Leontiadis, G. I., Tse, F., Mahadevan, U., van der Woude, C. J., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.12.003 · Cited by 473
Self-citation
Metadata
- Authors
- Weber‐Schoendorfer, C., Chambers, C., Wacker, E., Beghin, D., Bernard, N., on behalf of the Network of French Pharmacovigilance Centers, Shechtman, S., Johnson, D., Cuppers‐Maarschalkerweerd, B., Pistelli, A., Clementi, M., Winterfeld, U., Eleftheriou, G., Pupco, A., Kao, K., Malm, H., Elefant, E., Koren, G., Vial, T., Ornoy, A., Meister, R., & Schaefer, C.
- Venue
- Arthritis & Rheumatology
- Publisher
- Wiley
- Published
- 2014-04-28
- Volume
- 66
- Issue
- 5
- Pages
- 1101-1110
- ISSN
- 2326-5191 (ISSN-L)
- 2326-5205
- OpenAlex
- W1962974240
- Cited by
- 209
- References
- 2
- FWCI
- 17.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pregnancy Outcome After Methotrexate Treatment for Rheumatic Disease Prior to or During Early Pregnancy: A Prospective Multicenter Cohort Study. https://app.cochat.ai/papers/10.1002/art.38368
- The paper
- Weber‐Schoendorfer, C., Chambers, C., Wacker, E., Beghin, D., Bernard, N., on behalf of the Network of French Pharmacovigilance Centers, Shechtman, S., Johnson, D., Cuppers‐Maarschalkerweerd, B., Pistelli, A., Clementi, M., Winterfeld, U., Eleftheriou, G., Pupco, A., Kao, K., Malm, H., Elefant, E., Koren, G., Vial, T., . . . Schaefer, C. (2014). Pregnancy Outcome After Methotrexate Treatment for Rheumatic Disease Prior to or During Early Pregnancy: A Prospective Multicenter Cohort Study. Arthritis & Rheumatology. https://doi.org/10.1002/art.38368
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.